文献速递胸部肿瘤放疗

放射治疗与小细胞肺癌患者心脏事件发生率升高相关

Radiation Therapy Is Associated With an Increased Incidence of Cardiac Events in Patients with Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-06-06

基于美国监测、流行病学和最终结果计划与医疗保险理赔数据库,纳入2000至2011年7060例接受化疗±放疗的小细胞肺癌患者,倾向性评分匹配及多因素分析显示放疗与心脏事件风险升高相关,5年心脏事件绝对增加约5%,局限期患者可达10%。

要点

  • 化疗+放疗组与单纯化疗组60个月心脏事件累积发生率分别为44.1%与39%(P = .008)。
  • 倾向性评分匹配后(5286例)60个月心脏事件发生率为43%与38.6%(P = .033)。
  • 多因素分析显示放疗与心脏事件相关(HR 1.20;95%CI 1.06-1.37;P = .005)。

核心结论

  • 小细胞肺癌患者治疗后发生心脏事件的风险显著,放疗与5年心脏事件率绝对增加约5%相关,局限期患者可达10%。
  • 作者认为应对小细胞肺癌患者进一步评估心脏风险管理及心脏保护性放疗技术。

研究设计与样本

  • 基于美国监测、流行病学和最终结果计划与医疗保险理赔数据库的队列分析,纳入2000至2011年7060例接受化疗±放疗的小细胞肺癌患者,其中局限期2892例、广泛期4168例。
  • 采用倾向性评分匹配(按实际/理论放疗开始日期匹配以预防不死时间偏倚,再进行全倾向性评分匹配平衡临床特征)及多因素分析,并生成累积发生率函数曲线。

主要发现

  • 局限期与广泛期合并分析,化疗+放疗组与单纯化疗组60个月心脏事件发生率分别为44.1%与39%(P = .008)。
  • 倾向性评分匹配后(5286例),化疗+放疗组与单纯化疗组60个月心脏事件发生率分别为43%与38.6%(P = .033)。
  • 仅分析局限期患者(2016例),化疗+放疗组与单纯化疗组60个月心脏事件发生率分别为50.3%与42%(P = .0231)。
  • 多因素分析显示放疗与心脏事件相关(HR 1.20;95%CI 1.06-1.37;P = .005)。
  • 局限期患者倾向性评分匹配后(1614例),化疗+放疗组与单纯化疗组60个月心脏事件发生率分别为51.7%与41.6%(P = .0042)。

临床怎么用

  • 作者认为应对小细胞肺癌患者进一步评估心脏风险管理及心脏保护性放疗技术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cardiac radiation dose was a predictor of inferior overall survival in the Radiation Therapy Oncology Group 0617 non-small cell lung cancer trial. We examined the association between radiation therapy (RT) and cardiac events (CE) for patients with small cell lung cancer (SCLC). METHODS AND MATERIALS: The US population-based Surveillance, Epidemiology, and End Results Program and Medicare claims databases were queried for rates of CE among patients with SCLC treated with chemotherapy (CTX) ± RT. Propensity score matching (PSM) and multivariate analysis were conducted. Patients were matched for actual/theoretical RT start date (to prevent immortal time bias) and then full PSM balanced clinical characteristics. Cumulative incidence function curves were generated. RESULTS: From 2000 to 2011, 7060 patients were included: 2892 limited-stage SCLC (LS-SCLC) and 4168 extensive-stage SCLC. Grouping LS-SCLC and extensive-stage SCLC together, the incidence of CE for the CTX + RT and CTX-only groups was 44.1% versus 39% at 60 months (P = .008). After PSM (5286 patients), the incidence of CE for the CTX + RT and CTX-only groups was 43% versus 38.6% at 60 months (P = .033). Analysis of only LS-SCLC (2016 patients) demonstrated that the incidence of CE for CTX + RT versus CTX-only groups was 50.3% versus 42% at 60 months (P = .0231). Multivariate analysis again demonstrated an association between CE and RT (hazard ratio 1.20; 95% confidence interval 1.06-1.37; P = .005). After PSM (1614 patients), the incidence of CE for CTX + RT versus CTX-only groups was 51.7% versus 41.6% at 60 months (P = .0042). CONCLUSIONS: Patients with SCLC are at significant risk of developing CE posttreatment; RT is associated with an absolute increase in the rate of CE at 5 years of approximately 5% for all patients with SCLC and up to 10% for patients with LS-SCLC. Cardiac risk management and cardiac-sparing RT techniques should be further evaluated for patients with SCLC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ferris MJ, Jiang R, Behera M, et al. Radiation Therapy Is Associated With an Increased Incidence of Cardiac Events in Patients with Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30191870. doi:10.1016/j.ijrobp.2018.05.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。